| $376M | ||
| $350M | ||
| $215M | ||
| $127M | ||
| $107M | ||
| $100M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses. The company is actively engaged in developing and bringing to market therapeutic candidates designed to address a spectrum of conditions such as blood cancers, solid tumors, and chronic inflammatory diseases. Its pipeline features key development programs including: INKmune: Aimed at treating women suffering from relapsed or refractory ovarian carcinoma and individuals diagnosed with high-risk myelodysplastic syndrome. INB03: An immunotherapy targeting patients with both hematologic malignancies and solid tumors. XPro1595: Under development for the treatment of Alzheimer's disease. INmune Bio holds licensing agreements with entities including Xencor, Inc., Immune Ventures, LLC, the University of Pittsburgh, and University College London. Established in 2015, INmune Bio is headquartered in Boca Raton, Florida.
Over the last 12 months, insiders at INmune Bio, Inc. have bought $0 and sold $0 worth of INmune Bio, Inc. stock.
On average, over the past 5 years, insiders at INmune Bio, Inc. have bought $272,455 and sold $1.97M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 10,000 shares for transaction amount of $52,868 was made by Moss David J (Chief Financial Officer) on 2024‑09‑30.
| 2024-09-30 | Moss David J | Chief Financial Officer | 10,000 0.0481% | $5.29 | $52,868 | +7.33% | ||
| 2024-09-12 | Tesi Raymond Joseph | President and CEO | 15,380 0.0776% | $6.38 | $98,048 | -9.47% | ||
| 2024-09-12 | Moss David J | Chief Financial Officer | 7,690 0.0388% | $6.38 | $49,024 | -9.47% | ||
| 2024-06-25 | Juda Scott | director | 5,000 0.0257% | $7.27 | $36,350 | +0.91% | ||
| 2024-04-19 | Tesi Raymond Joseph | President and CEO | 18,028 0.0984% | $8.32 | $149,993 | -11.47% | ||
| 2024-04-19 | Lowdell Mark William | Chief Scientific Officer | 14,423 0.0788% | $8.32 | $119,999 | -11.47% | ||
| 2024-04-19 | Moss David J | CFO, Treasurer & Secretary | 18,028 0.0984% | $8.32 | $149,993 | -11.47% | ||
| 2024-04-19 | Juda Scott | director | 29,603 0.1617% | $8.32 | $246,297 | -11.47% | ||
| 2023-11-10 | Juda Scott | director | 7,000 0.0391% | $6.95 | $48,650 | +37.03% | ||
| 2023-07-12 | Sale | Schroeder Timothy j | director | 10,000 0.061% | $11.01 | $110,085 | -6.47% | |
| 2023-03-17 | Moss David J | CFO, Treasurer & Secretary | 2,500 0.0136% | $6.42 | $16,063 | +27.24% | ||
| 2022-05-26 | Tesi Raymond Joseph | President and CEO | 6,300 0.0355% | $6.41 | $40,383 | +21.33% | ||
| 2022-05-26 | Moss David J | CFO, Treasurer & Secretary | 7,700 0.0425% | $6.27 | $48,279 | +21.33% | ||
| 2021-11-17 | Juda Scott | director | 2,500 0.0147% | $13.55 | $33,875 | -37.24% | ||
| 2021-11-03 | Sale | Tesi Raymond Joseph | President and CEO | 3,626 0.0214% | $20.00 | $72,520 | -56.78% | |
| 2021-11-03 | Sale | Lowdell Mark William | Chief Scientific Officer | 701 0.0041% | $20.00 | $14,020 | -56.78% | |
| 2021-11-03 | Sale | Moss David J | CFO, Treasurer & Secretary | 1,025 0.0061% | $20.00 | $20,500 | -56.78% | |
| 2021-10-27 | Sale | Tesi Raymond Joseph | President and CEO | 6,517 0.0381% | $20.00 | $130,340 | -56.13% | |
| 2021-10-27 | Sale | Lowdell Mark William | Chief Scientific Officer | 2,357 0.0138% | $20.00 | $47,140 | -56.13% | |
| 2021-10-27 | Sale | Moss David J | CFO, Treasurer & Secretary | 2,079 0.0122% | $20.00 | $41,580 | -56.13% |
| Tesi Raymond Joseph | President and CEO | 1554106 5.8457% | $1.97M | 7 | 4 | <0.0001% |
| Lowdell Mark William | Chief Scientific Officer | 1510806 5.6829% | $1.92M | 2 | 4 | <0.0001% |
| Moss David J | Chief Financial Officer | 1285869 4.8368% | $1.63M | 8 | 4 | <0.0001% |
| Powers Linda F | director | 210000 0.7899% | $266,700.00 | 2 | 1 | <0.0001% |
| Schroeder Timothy j | director | 82187 0.3091% | $104,377.49 | 0 | 6 | |
| Juda Scott | director | 71603 0.2693% | $90,935.81 | 6 | 0 | <0.0001% |
$95,303,339 | 30 | -13.78% | $32.31M | |
INmune Bio, Inc. (INMB) | $2,983,776 | 25 | -16.47% | $33.76M |
$523,320 | 24 | 94.37% | $34.27M | |
$226,127 | 22 | -27.62% | $50.24M | |
$241,165 | 22 | -16.72% | $32.63M | |
$351,813 | 19 | 21.51% | $32.18M | |
$3,556,951 | 18 | 9.64% | $41.64M | |
$13,486,672 | 11 | 82.26% | $45.25M | |
$189,648 | 9 | -52.20% | $32.31M | |
$654,995 | 7 | -60.00% | $26.37M | |
$5,306,958 | 5 | 11.70% | $42.29M | |
$208,889 | 5 | 44.22% | $46.61M | |
$26,254,149 | 5 | 49.97% | $32.67M | |
$657,791 | 4 | -52.05% | $36M | |
$67,369,250 | 3 | -22.09% | $45.44M | |
$16,526,031 | 2 | -0.85% | $28.1M | |
$100,266 | 2 | 3.17% | $24.86M | |
$4,030 | 1 | 9.14% | $42.79M | |
$30,190 | 1 | -42.39% | $31.69M |
| Increased Positions | 36 | +41.86% | 916,161 | +19% |
| Decreased Positions | 34 | -39.53% | 625,009 | -12.96% |
| New Positions | 12 | New | 465,485 | New |
| Sold Out Positions | 14 | Sold Out | 303,920 | Sold Out |
| Total Postitions | 88 | +2.33% | 5M | +6.04% |
| Blackrock, Inc. | $1,828.00 | 4.4% | 1.19M | +14,435 | +1.23% | 2025-09-30 |
| Vanguard Group Inc | $1,349.00 | 3.25% | 876,292 | +28,541 | +3.37% | 2025-09-30 |
| Geode Capital Management, Llc | $723.00 | 1.74% | 469,440 | +79,509 | +20.39% | 2025-09-30 |
| State Street Corp | $437.00 | 1.05% | 283,833 | +8,441 | +3.06% | 2025-09-30 |
| Raymond James Financial Inc | $413.00 | 0.99% | 268,460 | -65,017 | -19.5% | 2025-09-30 |
| Northern Trust Corp | $291.00 | 0.7% | 189,116 | +24,699 | +15.02% | 2025-09-30 |
| Susquehanna International Group, Llp | $242.00 | 0.58% | 156,954 | +137,009 | +686.93% | 2025-09-30 |
| Ubs Group Ag | $240.00 | 0.58% | 155,522 | -293,699 | -65.38% | 2025-09-30 |
| Westside Investment Management, Inc. | $159.00 | 0.38% | 103,450 | +82,075 | +383.98% | 2025-09-30 |
| Morgan Stanley | $117.00 | 0.28% | 75,710 | -27,028 | -26.31% | 2025-09-30 |